Antiparasitic Therapy

June 2011
Mayo Clinic Proceedings;Jun2011, Vol. 86 Issue 6, p561
Academic Journal
Parasitic diseases affect more than 2 billion people globally and cause substantial morbidity and morbidlty, particularly among the world's poorest people. This overview focuses on the treatment of the major protozoan and helminth infections In humans. Recent developments In anti parasitic therapy include the expansion of artemisinin-based therapies for malaria, new drugs for soil-transmitted helminths and intestinal protozoa, expansion of the indications for antiparasitic drug treatment in patients with Chagas disease, and the use of combination therapy for leishmanlasis and human African trypanosomiasis.


Related Articles

  • A Schistosome cAMP-Dependent Protein Kinase Catalytic Subunit Is Essential for Parasite Viability. Swierczewski, Brett E.; Davies, Stephen J. // PLoS Neglected Tropical Diseases;Aug2009, Vol. 3 Issue 8, p1 

    Eukaryotes, protozoan, and helminth parasites make extensive use of protein kinases to control cellular functions, suggesting that protein kinases may represent novel targets for the development of anti-parasitic drugs. Because of their central role in intracellular signaling pathways, cyclic...

  • Avoiding detection: parasites and the immune system. Harnett, William // Biologist;Oct2002, Vol. 49 Issue 5, p222 

    Provides information on parasitic infections in humans. Background on protozoan and helminth parasites; Description of the human immune system; Strategies employed by parasites to evade the host immune response.

  • Human African trypanosomiasis—neurological aspects. Kennedy, Peter G. E. // Journal of Neurology;Apr2006, Vol. 253 Issue 4, p411 

    Human African Trypanosomiasis (HAT),which is also known as sleeping sickness, is a major cause of death and disability in 36 countries in sub-Saharan Africa. The disease is caused by the protozoan parasite of the Trypanosoma genus which is transmitted by the bite of the tsetse fly. The two types...

  • Chemosensitizers in Drug Transport Mechanisms Involved in Protozoan Resistance. Pradines, Bruno; Pag�s, Jean-Marie; Barbe, Jacques // Current Drug Targets - Infectious Disorders;Dec2005, Vol. 5 Issue 4, p411 

    The emergence and spread of antiparasitic drug resistance pose a severe and increasing public health threat. Failures in prophylaxis or those in treatment with quinolines, hydroxynaphtoquinones, sesquiterpenic lactones, antifolate drugs, arsenic and antimony containing drugs sulfamides induce...

  • Weak Cytotoxic Activity of Miltefosine Against Clinical Isolates of Acanthamoeba spp. Mrva, M.; Garajová, M.; Lukáč, M.; Ondriska, F. // Journal of Parasitology;Jun2011, Vol. 97 Issue 3, p538 

    Hexadecylphosphocholine (miltefosine) is an anticancer drug active in vitro against various protozoan parasites, and recently used for the treatment of disseminated Acanthamoeba infection. In the present study, we present results of weak cytotoxic activity of this potential amoebicidal agent for...

  • The Challenges of Chagas Disease Grim Outlook or Glimmer of Hope. Tarleton, Rick L.; Reithinger, Richard; Urbina, Julio A.; Kitron, Uriel; Gürtler, Ricardo E. // PLoS Medicine;Dec2007, Vol. 4 Issue 12, pe332 

    The authors discuss the key challenges that undermine the control of Chagas disease and that must be urgently addressed to ensure long-term, sustainable control.

  • 3D QSAR STUDIES ON A SERIES OF 1,3,4-THIADIAZOLE-2-ARYLHYDRAZONE DERIVATIVES AS ANTITRYPANOSOMAL AGENTS. THE k-NEAREST NEIGHBOR MOLECULAR FIELD ANALYSIS APPROACH. Noolvi, Malleshappa N.; Patel, H. M.; Sethi, Navdeep Singh // Digest Journal of Nanomaterials & Biostructures (DJNB);Jun2010, Vol. 5 Issue 2, p519 

    Megazol is a highly active compound against Trypanosoma cruzi, and has become a core structure for the design of new trypanocidal agent. Recently, a new potent trypanocide agent Brazilizone A (a derivatives of megazol), was identified which presents an IC50 two fold more potent than the...

  • Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African Trypanosomiasis. Chappuis, François; Udayraj, Nitya; Stietenroth, Kai; Meussen, Ann; Bovier, Patrick A. // Clinical Infectious Diseases;9/1/2005, Vol. 41 Issue 5, p748 

    Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kin, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with...

  • Opportunities and Challenges in Antiparasitic Drug Discovery. Pink, Richard; Hudson, Alan; Mouriès, Marie-Annick; Bendig, Mary // Nature Reviews Drug Discovery;Sep2005, Vol. 4 Issue 9, p727 

    New antiparasitic drugs are urgently needed to treat and control diseases such as malaria, leishmaniasis, sleeping sickness and filariasis, which affect millions of people each year. However, because the majority of those infected live in countries in which the prospects of any financial return...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics